Precision Biosciences Inc
DTIL
Get informed when a big investor buys or sells
+ FollowMarket Cap$100.96M
Close$
$16.72
128.1% upside
Current Fair Value
128.1% upsideUndervalued by 128.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $100.96 Million |
|---|---|
| Enterprise Value | $30.05 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.56 |
| Beta | 1.25 |
| Outstanding Shares | 24,634,443 |
Return
| Return on Equity | -57.29% |
|---|---|
| Return on Assets | -30.30% |
| Return on Invested Capital | -26.47% |
Valuation & Multiples
| P/E Ratio | -2.15 |
|---|---|
| PEG | 20.82 |
| Price to Sales | 7.33 |
| Price to Book Ratio | 2.44 |
| Enterprise Value to Revenue | 0.67 |
| Enterprise Value to EBIT | -0.83 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.95 |
| Debt to Equity | 0.37 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 21, 2026
EPS Estimate
$-0.66
Average shareholder expectationRevenue Estimate
$4.05 M
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.71
Average shareholder expectationRevenue Estimate
$1.40 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 20,400▲ Infinity% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 65.56%▼ 62.18% |
|---|---|
| Total Invested | $88.11M▲ 40.32% |
| Investors Holding | 78▲ 11.00% |
ESG Score
No data
About Precision Biosciences Inc
CEO: Matthew Kane